Drug companies face many challenges in pediatric clinical research. Pediatric trials come with a high level of complexity and cost. In order for professionals to carryout a successful pediatric drug development plan, they need the right infrastructure and information to avoid obstacles such as slow recruitment, noncompliance and difficulties in developing the right study criteria and protocol. When conducting research on children, drug companies must ensure that ethical boundaries are observed in both the design and execution of pediatric trials.

The purpose of this conference is to identify the ethical, economic, regulatory and technical considerations when conducting clinical studies on children. Discussions include site development and recruiting, the execution of clinical studies overseas, including developing countries, issues with timeliness and agency incentives and requirements. The 3rd Pediatric Clinical Trials conference provides a forum in which industry professionals can evaluate the current issues in pediatric drug development and discuss approaches and best practices for overcoming these challenges.

I hope you can join us for this valuable educational and networking opportunity.